Equities

Tanvex BioPharma Inc

Tanvex BioPharma Inc

Actions
Health CarePharmaceuticals and Biotechnology
  • Price (TWD)70.10
  • Today's Change0.10 / 0.14%
  • Shares traded153.22k
  • 1 Year change+8.59%
  • Beta--
Data delayed at least 20 minutes, as of Sep 20 2024.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Financials data is unavailable for this security.

Cash flow in TWDView more

In 2023, cash reserves at Tanvex BioPharma Inc fell by 405.48m. Cash Flow from Financing totalled 1.08bn or 1,757.90% of revenues. In addition the company used 1.43bn for operations while cash used for investing totalled 83.57m.
Cash flow per share-10.64
Price/Cash flow per share--
Book value per share9.01
Tangible book value per share8.98
More ▼

Balance sheet in TWDView more

Tanvex BioPharma Inc has a Debt to Total Capital ratio of 54.05%, a lower figure than the previous year's 92.92%.
Current ratio3.64
Quick ratio3.32
Total debt/total equity1.18
Total debt/total capital0.5405
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.